Efficacy evaluation of Tiotropium Respimat with AeroChamber Plus

Efficacy evaluation of Tiotropium Respimat with AeroChamber Plus - Inhalation therapy using Tiotropium Respimat with AeroChamber Plus

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013980

Enrollment

Registered

2014-05-17

Start date

2014-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD

Interventions

Inhalation of Tiotropium Respimat with AeroChamber Plus Inhalation of Tiotropium Respimat without AeroChamber Plus

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients >= 20 years of age with a diagnosis of stage 1 - 3 COPD. 2. Patients continuing use of tiotropium respimat. 3. Patients planning to start tiotropium respimat. 4. Patients who are not using long acting be-ta 2-agonist (LABA) or inhaled corticosteroid (ICS)/LABA combination.

Exclusion criteria

Exclusion criteria: 1. Known severe allergy to any drugs. 2. Patients with benign prostatic hypertrophy or glaucoma. 3. Patients who cannot parchase AeroChamber Plus. 4. Patients who cannot use tiotropium respimat with inhalation assistance.

Design outcomes

Primary

Measure	Time frame
Change of forced expiratory volume in 1 second (FEV1) after inhalation therapy	—

Countries

Japan

Contacts

Public ContactTakashi Ogasawara

Hamamatsu Medical Center Department of respiratory medicine

shikatarawasagao@gmail.com053-453-7111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026